Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 27.6483
- Book/Share 32.2885
- PB 5.1034
- Debt/Equity 0.669
- CurrentRatio 1.2574
- ROIC 0.1217
- MktCap 396472214600.0
- FreeCF/Share 7.6781
- PFCF 21.3455
- PE 17.5905
- Debt/Assets 0.2698
- DivYield 0.0305
- ROE 0.3112
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J. , July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Read More
S&P 500 Gains and Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
Published: July 16, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes ticked higher Wednesday as President Donald Trump refuted reports that he is planning the immediate dismissal of Federal Reserve Chair Jerome Powell and questions about his legal ability to do so.
Read More
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Published: July 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET Company Participants Darren Snellgrove - Corporate Participant Jennifer L. Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Joaquin Duato - CEO & Chairman John C.
Read More
2 Dividend Giants Every Passive Income Investors Should Own
Published: July 16, 2025 by: 24/7 Wall Street
Sentiment: Positive
It's never been easier as a passive income investor to give your yield a bit of a jolt with the rise of covered call (and premium income) ETFs that trade off a bit of upside potential for some premiums.
Read More
Johnson & Johnson Stock Jumps on Strong Earnings, Higher Outlook
Published: July 16, 2025 by: Investopedia
Sentiment: Positive
Johnson & Johnson (JNJ) shares surged Wednesday after the company reported second-quarter results that topped estimates and the company lifted its full-year outlook.
Read More
Final Trades: Johnson & Johnson, ICE and the IBIT
Published: July 16, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their stop stocks to watch for the second half.
Read More
Top Stock Movers Now: J&J, ASML, Tesla, and More
Published: July 16, 2025 by: Investopedia
Sentiment: Negative
Major U.S. equities indexes were little changed at midday Wednesday after a report on wholesale inflation showed a surprising slowdown in June.
Read More
PPI Remained Unchanged
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Pre-market futures are climbing into the green this morning, following a cooler-than-expected wholesale inflation report and better-than-expected financial Q2 earnings numbers out before the bell today. After starting off roughly -0.1% across the board, we're currently up +160 points on the Dow, +13 points on the S&P 500 and +14 on the Nasdaq.
Read More
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
Read More
J&J CFO: We're pleased with the engagement with the Trump administration
Published: July 16, 2025 by: CNBC Television
Sentiment: Positive
Johnson & Johnson CFO Joseph Wolk said Wednesday that the company is pleased with its engagement with the Trump administration, especially around tax policy, crediting the 2017 tax cuts for driving J&J's $55 billion U.S. investment and expanded biopharma manufacturing.
Read More
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Johnson & Johnson delivers earnings beat, raises full year sales and profit guidance
Published: July 16, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) shares edged higher premarket as the healthcare firm reported an earnings beat for the second quarter and raised its full-year guidance. For Q2, revenue of $23.74 billion was up 5.8% year-over-year and ahead of estimates of $22.83 billion, driven by strong sales of cancer treatments, notably Darzalex, and medical devices.
Read More
Top Beauty and Cosmetics Stocks That May Drive Long-Term Growth
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
EL, COTY and ULTA are tapping AI, e-commerce, and clean beauty to ride the next wave of long-term industry growth.
Read More
Pre-Markets in the Red to Start a Fresh Week
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Pre-market futures are notably lower than Friday afternoon's close on all major indexes, though they are beginning to climb out of the muck of fresh tariff threats as early trading warms up to start a new trading week. We had gotten back up to or near record market highs last week before new tariff threats from President Trump threw a damp towel over stock market heat.
Read More
Wells Fargo, Citi, Netflix, J&J, and More Stocks to Watch This Week
Published: July 13, 2025 by: Barrons
Sentiment: Neutral
Financials make up half of the 38 S&P 500 companies slated to report quarterly results this week. The week's big economic news will be the consumer price index for June.
Read More
Pre-Markets Red on Trump's Tariff Threats to Canada
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Pre-Markets Red on Trump's Tariff Threats to Canada.
Read More
Mar Vista U.S. Quality Q2 2025 Top Contributors And Detractors
Published: July 11, 2025 by: Seeking Alpha
Sentiment: Positive
Microsoft, Broadcom, and Oracle were among the portfolio's top contributors for the quarter. Alternatively, Apple, Johnson & Johnson, and Berkshire Hathaway detracted from performance. Microsoft shares rebounded in calendar Q2 following a strong fiscal Q3 2025 (March quarter), driven by accelerating demand for AI-related Azure services.
Read More
Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Read More
3 AI-Driven Medical Device Stocks to Watch in 2025
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.
Read More
I Have Invested in Dividends For 15 Years—These Dividend Aristocrats Built My Passive Income Stream
Published: July 09, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend aristocrats haven't disappointed me in 15 years and won't disappoint you either.
Read More
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Read More
Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?
Published: July 09, 2025 by: Seeking Alpha
Sentiment: Positive
JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on the 16th ofJuly. JNJ has a long history of beating consensus EPS estimates by 5.5% on average. The Q2 sales growth could potentially be the weakest of the 4 quarters of the year.
Read More
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Published: July 08, 2025 by: CNBC
Sentiment: Neutral
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Dogs of the Dow: These Are The Best Dividend Stocks in July 2025
Published: July 08, 2025 by: 24/7 Wall Street
Sentiment: Positive
If you're keen on following the Dogs of the Dow investing strategy, here are three stocks with a high-yield.
Read More
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend
Published: July 07, 2025 by: 24/7 Wall Street
Sentiment: Positive
The vast majority of investors don't have hundreds of thousands to bet on each stock.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Negative
JNJ's MedTech unit eyes second-half growth despite China headwinds, U.S. competition and tariff pressure.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100